Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 9Thoracic 6Head & Neck 6Genitourinary 5Gastrointestinal 5Breast 3Other solid neoplasm 2Gynecologic 2Myeloid 1Lymphoid 1Endocrine 1

Conditions

Uveal Melanoma 1Primary Myelofibrosis 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1

Interventions

tipifarnib 1ruxolitinib 1ripretinib 1peginterferon alfa-2a 1cobimetinib 1cc-486 1bemcentinib 1avelumab 1Vemurafenib 1Standard of Care 1Quality of Life 1Practice Guidelines as Topic 1Pentetic Acid 1Pemetrexed 1Patient Reported Outcome Measures 1Palliative Care 1PLX8394 1Nurse Clinicians 1Molecular Diagnostic Techniques 1Minocycline 1Ipilimumab 1Interferon alpha-2 1Injections 1In Situ Hybridization, Fluorescence 1Immunotherapy 1Imatinib Mesylate 1Heparin 1Fentanyl 1Drug Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × avelumab × Myeloid × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡